mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Clinical Cancer Research

• Publication date

  2015-11-06

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-15-1772PMID 26546619PMCID PMC4858320
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• TUSC4 functions as a tumor suppressor by regulating BRCA1 stability.

  2015cited by this paper
• Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer

  2015influential reference
• Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells

  2014cited by this paper
• Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype

  2014cited by this paper
• New Strategies for Triple-Negative Breast Cancer—Deciphering the Heterogeneity

  2014influential reference
• mTOR kinase inhibitor sensitizes T-cell lymphoblastic leukemia for chemotherapy-induced DNA damage via suppressing FANCD2 expression

  2014cited by this paper
• Genome-wide Transcriptome Profiling of Homologous Recombination DNA Repair

  2014influential reference
• Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer

  2014cited by this paper
• DNA double-strand breaks promote methylation of histone H3 on lysine 9 and transient formation of repressive chromatin

  2014influential reference
• BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency

  2013cited by this paper
• Establishment of Patient‐Derived Xenograft (PDX) Models of Human Breast Cancer

  2013cited by this paper
• mTOR regulates DNA damage response through NF-κB-mediated FANCD2 pathway in hematopoietic cells

  2013cited by this paper
• Methylation of SUV39H1 by SET7/9 results in heterochromatin relaxation and genome instability

  2013cited by this paper
• Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance

  2013cited by this paper
• Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double-strand breaks.

  2013cited by this paper
• Merging high-quality biochemical fractionation with a refined flow cytometry approach to monitor nucleocytoplasmic protein expression throughout the unperturbed mammalian cell cycle

  2013cited by this paper
• Zinc finger protein 668 interacts with Tip60 to promote H2AX acetylation after DNA damage

  2013cited by this paper
• The mTOR Signalling Pathway in Human Cancer

  2012cited by this paper
• BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation

  2012cited by this paper
• Prevalence of BRCA mutations in an unselected population of triple‐negative breast cancer

  2012influential reference
• PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.

  2012influential reference
• Applications of Connectivity Map in drug discovery and development.

  2012cited by this paper
• Emerging targeted therapies in triple-negative breast cancer.

  2012cited by this paper
• mTOR in breast cancer: differential expression in triple-negative and non-triple-negative tumors.

  2012cited by this paper
• Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

  2012cited by this paper
• Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer.

  2012cited by this paper
• Poly(ADP‐Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic

  2011cited by this paper
• COMPROMISED CDK1 ACTIVITY SENSITIZES BRCA-PROFICIENT CANCERS TO PARP INHIBITION

  2011influential reference
• CA : A Cancer Journal for Clinicians

  2011cited by this paper
• The mTOR Inhibitor Rapamycin Suppresses DNA Double-Strand Break Repair

  2010cited by this paper
• Poly(ADP-Ribose) Polymerase Inhibition: “Targeted” Therapy for Triple-Negative Breast Cancer

  2010cited by this paper
• A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer

  2010cited by this paper
• A subset of the histone H3 lysine 9 methyltransferases Suv39h1, G9a, GLP, and SETDB1 participate in a multimeric complex.

  2010influential reference
• Triple-negative breast cancer.

  2010cited by this paper
• Heterochromatic Genome Stability Requires Regulators of Histone H3 K9 Methylation

  2009cited by this paper
• mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

  2009cited by this paper
• Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)

  2009cited by this paper
• BRIT1/MCPH1 Links Chromatin Remodeling to DNA Damage Response

  2009cited by this paper
• Quantitative Nuclear Proteomics Identifies mTOR Regulation of DNA Damage Response*

  2009cited by this paper
• A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.

  2008cited by this paper
• Triple-negative breast cancer.

  2008cited by this paper
• Homologous recombination in DNA repair and DNA damage tolerance

  2008influential reference
• TOR Signaling Is a Determinant of Cell Survival in Response to DNA Damage

  2007cited by this paper
• Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype

  2007cited by this paper
• The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease

  2006cited by this paper
• Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies

  2006cited by this paper
• The tor pathway: a target for cancer therapy

  2004cited by this paper
• mTOR Controls Cell Cycle Progression through Its Cell Growth Effectors S6K1 and 4E-BP1/Eukaryotic Translation Initiation Factor 4E

  2004cited by this paper
• The DNA methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase.

  2003cited by this paper
• Loss of the Suv 39 h Histone Methyltransferases Impairs Mammalian Heterochromatin and Genome Stability

  2001cited by this paper
• Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability.

  2001cited by this paper
• Involvement of poly(ADP-ribose) polymerase in base excision repair.

  1999cited by this paper
• Role of the human RAD51 protein in homologous recombination and double-stranded-break repair.

  1998cited by this paper
• Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining

  1975cited by this paper

• Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment

  2026cites this paper
• Metformin Sensitizes PTEN-deficient Prostate Cancer to PARP Inhibitors by Rebuilding NADP+ Homeostasis

  2026cites this paper
• An integrative multi-omics analysis leveraging Mendelian randomization and subsequent experimental validation prioritizes glutathione S-transferase mu 5 (GSTM5) as a genomic stability-related gene and a therapeutic vulnerability to PLK1 inhibition in breast cancer.

  2026cites this paper
• Combination of PARP and KRASG12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC.

  2026cites this paper
• DNA damage repair (DDR) related prognostic risk model in multiple myeloma based on single-cell and bulk sequencing.

  2025cites this paper
• The novel tRNA-derived fragment, tiRNA-Met, inhibits the malignant progression of triple-negative breast cancer by regulating RANBP3L via a targeted interaction with SNRPA

  2025cites this paper
• Inhibition of the STAT3/Fanconi anemia axis is synthetic lethal with PARP inhibition in breast cancer

  2025cites this paper
• Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment

  2025cites this paper
• PARPs and PARP inhibitors: molecular mechanisms and clinical applications

  2025cites this paper
• Hexavalent chromium promotes malignant transformation via enhanced translation of SUV39H1.

  2025cites this paper
• Circulating Tumor DNA Profiling Identifies Actionable Mutations as Prognostic Markers in Advanced Neuroendocrine Tumors

  2025cites this paper
• Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment

  2024cites this paper
• BRCA and Beyond: Impact on Therapeutic Choices Across Cancer

  2024cites this paper
• Developing combination therapies with biologics in triple-negative breast cancer

  2024cites this paper
• Synergistic Effect of Ubiquitin-Specific Protease 14 and Poly(ADP-Ribose) Glycohydrolase Co-Inhibition in BRCA1-Mutant, Poly(ADP-Ribose) Polymerase Inhibitor-Resistant Triple-Negative Breast Cancer Cells

  2024cites this paper
• ATM inhibition exploits checkpoint defects and ATM-dependent double strand break repair in TP53-mutant glioblastoma

  2024cites this paper
• BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges

  2024cites this paper
• Enhancing the anti-tumor response by combining DNA damage repair inhibitors in the treatment of solid tumors.

  2023cites this paper
• Development of PARP Inhibitors in Targeting Castration-Resistant Prostate Cancer.

  2023cites this paper
• Rational Combinations of PARP Inhibitors with HRD-Inducing Molecularly Targeted Agents.

  2023cites this paper
• SUV39H1 Expression as a Guideline for Omitting Radiotherapy in Lymph Node-positive Triple-negative Breast Cancer Patients

  2023cites this paper
• Pilot clinical trial and phenotypic analysis in chemotherapy-pretreated, metastatic triple-negative breast cancer patients treated with oral TAK-228 and TAK-117 (PIKTOR) to increase DNA damage repair de�ciency followed by cisplatin and nab paclitaxel

  2023cites this paper
• Combination Treatment Strategies to Overcome PARP Inhibitor Resistance

  2023cites this paper
• Pilot clinical trial and phenotypic analysis in chemotherapy-pretreated, metastatic triple-negative breast cancer patients treated with oral TAK-228 and TAK-117 (PIKTOR) to increase DNA damage repair deficiency followed by cisplatin and nab paclitaxel

  2023cites this paper
• Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens

  2023cites this paper
• PARP inhibitors: enhancing efficacy through rational combinations

  2023cites this paper
• The role of PARP inhibitor combination therapy in ovarian cancer

  2023cites this paper
• SUV39H1 is a prognosis and immune microenvironment-related biomarker in diffuse large B-cell lymphoma

  2023cites this paper
• A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer

  2023cites this paper
• Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma

  2023cites this paper
• Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges

  2023cites this paper
• Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status

  2023cites this paper
• PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies

  2022cites this paper
• Synergistic effect of combined PI3 kinase inhibitor and PARP inhibitor treatment on BCR/ABL1-positive acute lymphoblastic leukemia cells

  2022cites this paper
• Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors

  2022cites this paper
• Next-generation sequencing identifies potential novel therapeutic targets in Chinese HGSOC patients.

  2022cites this paper
• Combined inhibition of BADSer99 phosphorylation and PARP ablates models of recurrent ovarian carcinoma

  2022cites this paper
• Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors

  2022cites this paper
• PTEN‐PI3K pathway alterations in advanced prostate cancer and clinical implications

  2022cites this paper
• Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition

  2022cites this paper
• mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers

  2022cites this paper
• Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use

  2022cites this paper
• PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers

  2022cites this paper
• The role of epigenetic modifications in Colorectal Cancer Metastasis

  2022cites this paper
• Control of Breast Cancer Pathogenesis by Histone Methylation and the Hairless Histone Demethylase

  2021cites this paper
• DNA damage response inhibitors: An avenue for TNBC treatment.

  2021cites this paper
• Glycogen synthase kinase 3β inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer

  2021cites this paper
• Small-Molecule Drug Discovery in Triple Negative Breast Cancer: Current Situation and Future Directions.

  2021cites this paper
• Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studies

  2021cites this paper
• Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells

  2021cites this paper
• AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?

  2021cites this paper
• Adaptive Evolution: How Bacteria and Cancer Cells Survive Stressful Conditions and Drug Treatment.

  2021cites this paper
• DNA Damage Repair Inhibitor for Breast Cancer Treatment.

  2021cites this paper
• Clinical expression and prognosis of SUV39H1 in diffuse large B-cell lymphoma

  2021cites this paper
• BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair

  2021cites this paper
• Targeting DNA damage repair pathways in pancreas cancer

  2021cites this paper
• Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer

  2021cites this paper
• Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy

  2021cites this paper
• Microarray analysis of breast cancer gene expression profiling in response to 2-deoxyglucose, metformin, and glucose starvation

  2021cites this paper
• Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy.

  2021cites this paper
• Hydroxychloroquine Synergizes With The PI3K Inhibitor BKM120 to Exhibit Antitumor E�cacy Independent of Autophagy

  2021cites this paper
• PARP1 and PRC2 double deficiency promotes BRCA‐proficient breast cancer growth by modification of the tumor microenvironment

  2020cites this paper
• The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer

  2020cites this paper
• Possible Novel Therapeutic Targets in Lymphangioleiomyomatosis Treatment

  2020cites this paper
• Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers.

  2020cites this paper
• PARP and PARG inhibitors in cancer treatment.

  2020cites this paper
• GSK3β Inhibition Synergizes with PARP Inhibitors through the Induction of Homologous Recombination Deficiency in Colorectal Cancer

  2020cites this paper
• The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers

  2020cites this paper
• Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer

  2020cites this paper
• Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials

  2019cites this paper
• Application of bioinformatic software and tools for prediction of miRNAs suppressing mTOR/S6K1 signaling pathway as new targets of cancer therapy

  2019cites this paper
• Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer

  2019cites this paper
• Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology

  2019cites this paper
• Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors.

  2019cites this paper
• FKBP25 participates in DNA double-strand break repair

  2019cites this paper
• PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers

  2019cites this paper
• Genomic Instability in Kidney Cancer: Etiologies and Treatment Opportunities

  2019cites this paper
• The mTOR Inhibitor Everolimus Overcomes CXCR4-Mediated Resistance to Histone Deacetylase Inhibitor Panobinostat through Inhibition of p21 and Mitotic Regulators.

  2019cites this paper
• The DNA Damaging Revolution: PARP Inhibitors and Beyond.

  2019cites this paper
• Thyroid hormone receptor interactor 13 (TRIP13) overexpression associated with tumor progression and poor prognosis in lung adenocarcinoma.

  2018cites this paper
• Increased centrosome number in BRCA‐related breast cancer specimens determined by immunofluorescence analysis

  2018cites this paper
• State-of-the-art strategies for targeting the DNA damage response in cancer

  2018cites this paper
• Clinical Utility of Poly (ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer

  2018cites this paper
• Clinical Observation of Improved Outcomes of Patients With BRCA 1/2 Breast Cancer Treated With Everolimus Prior to DNA-Damaging Therapy.

  2018cites this paper
• Cytogenetic and Transcriptomic Analysis of Human Endometrial MSC Retaining Proliferative Activity after Sublethal Heat Shock

  2018cites this paper
• Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives

  2018cites this paper
• Everolimus-induced pulmonary toxicity

  2018cites this paper
• Systems biology approach reveals a link between mTORC1 and G2/M DNA damage checkpoint recovery

  2018cites this paper
• Towards rational design of RAD51-targeting prodrugs: platinumIV-artesunate conjugates with enhanced cytotoxicity against BRCA-proficient ovarian and breast cancer cells.

  2018cites this paper
• PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non‐small‐cell lung cancer

  2018cites this paper
• Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition

  2018cites this paper
• The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality.

  2018cites this paper
• Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies.

  2018cites this paper
• Anti-apoptotic effect of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) polymerase, against multiple organ damage induced by gamma irradiation in rats

  2018cites this paper
• PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy

  2017cites this paper
• The NuRD complex‐mediated p21 suppression facilitates chemoresistance in BRCA‐proficient breast cancer

  2017cites this paper
• Targeting DNA Damage Response Pathways in Cancer

  2017cites this paper
• MATHEMATICAL MODELING REVEALS THAT G2/M CHECKPOINT OVERRIDE

  2017cites this paper
• A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia

  2017cites this paper
• Triple negative breast cancer: the kiss of death

  2017cites this paper